Announcements

Swiss regulator allows supply for EPP patients before formal approval Melbourne, Australia and Baar, Switzerland, April 26 2012 Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that SCENESSE® (afamelanotide 16mg implant) has been accepted by two leading health insurers in Switzerland for full reimbursement for the prophylactic treatment of patients with erythropoietic protoporphyria (EPP), a rare genetic disease causing extreme intolerance of skin to light. SCENESSE® can be supplied with immediate effect to physicians who treat approximately 50 EPP patients in Switzerland. The costs of supply will be covered in full by the insurance companies. This is…

April 2012 US Bulletin CEO overview: US program update | US Phase III erythropoietic protoporphyria (EPP) protocol | FDA releases EPP patient interview footage | Vitiligo program presentation awarded

Entering commercialisation. March 2012 Corporate Update.

Appendix 3B - New issue announcement, application for quotation of additional securities and agreement

SCENESSE® (afamelanotide 16mg) to be trialled for rare disease in US Phase III Melbourne, Australia and Baar, Switzerland, March 15 2012 Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that it had reached an in principle agreement with the US Food and Drug Administration (FDA) to conduct a Phase III study of the novel drug SCENESSE® (afamelanotide 16mg implant) in the rare disease erythropoietic protoporphyria (EPP). Clinuvel is currently working to finalise the Phase III study (CUV039) protocol with the FDA following an End-of-Phase-II meeting held on Monday March 12. Study Design After the completion of pivotal EPP…

SCENESSE® (afamelanotide 16mg implant) data and clinical reports to be discussed with global dermatology audience Melbourne, Australia and Baar, Switzerland, March 15 2012 Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that data and observations from the Company’s lead clinical trial programs for its novel drug SCENESSE® (afamelanotide 16mg implant) will be presented at a series of meetings centred on the American Academy of Dermatology (AAD) meeting in San Diego held from March 15-20. Vitiligo: early US data, further encouraging observationsRepigmentation data and further clinical observations from Clinuvel’s open label Phase II US pilot trial of SCENESSE®…

February 2012 Clinuvel Newsletter CEO's outlook | Clinuvel files MAA for SCENESSE® | INSPIRE vitiligo program update | Media coverage | CEO interview online | Share price & financials

Report for the half year ended 31 December 2011.

Melbourne, Australia and Baar, Switzerland, February 13 2012 Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) wishes to advise in accordance with the terms and conditions of issue that the following unquoted share options have lapsed and forfeited. Class Number Exercise Price CUVAI Unlisted Options expiring various dates & various exercise prices 1,133,000 $8.60 Consequently there are now 2,610,000 unquoted conditional performance rights on issue and 35,000 unlisted share options on issue. - End - For more information contact:Darren KeamyCompany SecretaryT: +61 3 9660 4900E: This email address is being protected from spambots. You need JavaScript enabled to view it. Clinuvel is an Australian biopharmaceutical company focussed on developing its photoprotective drug, SCENESSE®…